BioXcel Therapeutics downgraded by UBS with a new price target
$BTAI
Biotechnology: Pharmaceutical Preparations
Health Care
UBS downgraded BioXcel Therapeutics from Buy to Neutral and set a new price target of $4.00 from $9.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/21/2024 | $9.00 → $4.00 | Buy → Neutral | UBS |
| 8/15/2023 | $40.00 → $4.00 | Buy → Neutral | Mizuho |
| 7/17/2023 | Buy → Neutral | Guggenheim | |
| 3/10/2023 | $20.00 → $22.00 | Buy → Hold | Jefferies |
| 12/1/2022 | $16.00 | Sell → Neutral | Goldman |
| 7/7/2022 | $19.00 | Buy | Mizuho |
| 4/6/2022 | $80.00 | Buy | BofA Securities |
| 2/16/2022 | $88.00 → $25.00 | Buy | UBS |
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 30, 2025 /PRNewswire/ -- The concept of AI in healthcare is no longer a novelty, experts are acknowledging AI algorithms, detection, and drug discovery are becoming indispensable tools. As medical errors continue to harm patients, healthcare experts are turning to AI to improve mistakes in medications, such as prescribing the wrong drug or wrong dose. As real-world deployment gains momentum, a number of tech and biotech firms are already translating AI healthcare innovation into clinical practice. Notable recent activity includes initiatives from Avant Technologies, Inc. (OTCQB:AVAI), Tempus AI, Inc
DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that an independent Data Safety Monitoring Board (DSMB) recommended that the SERENITY At-Home pivotal Phase 3 safety trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia continue without modification. The DSMB recommendation followed a review of unblinded safety data from the first 115 patients dosed as of the May 2
NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that the Nasdaq Hearings Panel granted the Company's request to continue its listing on The Nasdaq Stock Market. During a Nasdaq Panel hearing held on May 1, 2025, the Panel reviewed the Company's plan and strategies to regain compliance with Listing Rule 5550(b)(2) (the "MVLS (market value of listed securities) Rule"). As a result of the hearing, the Panel granted the Company's request for continued listing on The Nasdaq Stock Market and provided the Company until S